ZA783493B - Improvement in or relating to heterocyclic compounds - Google Patents
Improvement in or relating to heterocyclic compoundsInfo
- Publication number
- ZA783493B ZA783493B ZA00783493A ZA783493A ZA783493B ZA 783493 B ZA783493 B ZA 783493B ZA 00783493 A ZA00783493 A ZA 00783493A ZA 783493 A ZA783493 A ZA 783493A ZA 783493 B ZA783493 B ZA 783493B
- Authority
- ZA
- South Africa
- Prior art keywords
- relating
- improvement
- heterocyclic compounds
- heterocyclic
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2574077 | 1977-06-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA783493B true ZA783493B (en) | 1979-06-27 |
Family
ID=10232513
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA00783492A ZA783492B (en) | 1977-06-20 | 1978-06-19 | Cyclic amino acids |
| ZA00783493A ZA783493B (en) | 1977-06-20 | 1978-06-19 | Improvement in or relating to heterocyclic compounds |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA00783492A ZA783492B (en) | 1977-06-20 | 1978-06-19 | Cyclic amino acids |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US4278676A (it) |
| EP (4) | EP0027279A1 (it) |
| JP (2) | JPS5436275A (it) |
| AT (1) | AT368505B (it) |
| AU (2) | AU3724478A (it) |
| CA (1) | CA1107736A (it) |
| DK (2) | DK270278A (it) |
| ES (2) | ES470912A1 (it) |
| FI (2) | FI64376C (it) |
| IE (1) | IE47200B1 (it) |
| IT (2) | IT7868449A0 (it) |
| NO (3) | NO782128L (it) |
| NZ (1) | NZ187615A (it) |
| ZA (2) | ZA783492B (it) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3145474A1 (de) * | 1980-11-27 | 1982-09-02 | Kefalas A/S, Koebenhavn-Valby | 3-substituierte 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridinverbindungen, verfahren zu ihrer herstellung und diese enthaltende arzneimittel |
| DE3145473A1 (de) * | 1980-11-27 | 1982-08-26 | Kefalas A/S, Koebenhavn-Valby | 2-substituierte 4,5,6,7-tetrahydroisoxazolo (5,4-c) pyridin-3-on-verbindungen, verfahren zu ihrer herstellung und diese enthaltende arzneimittel |
| EP0083378A1 (en) * | 1981-12-22 | 1983-07-13 | Chugai Seiyaku Kabushiki Kaisha | Tetrahydronicotinamide derivatives, a process for producing the same and a pharmaceutical composition comprising the same |
| GB8314391D0 (en) * | 1983-05-24 | 1983-06-29 | Kefalas As | Heterocyclic compounds |
| IT1228426B (it) * | 1987-07-20 | 1991-06-17 | Ausimont Spa | Perossiacidi eterociclici |
| US4859666A (en) * | 1988-07-06 | 1989-08-22 | Bristol-Myers Company | THAZ derivatives for enhancement of cerebral function |
| CN1043051C (zh) * | 1994-07-22 | 1999-04-21 | 国际壳牌研究有限公司 | 制备氢化石蜡的方法 |
| US20050234093A1 (en) * | 2003-06-25 | 2005-10-20 | H. Lundbeck A/S | Treatment of depression and other affective disorders |
| WO2004112786A2 (en) | 2003-06-25 | 2004-12-29 | H. Lundbeck A/S | Gaboxadol for treating depression and other affective disorders |
| AR045540A1 (es) | 2003-09-05 | 2005-11-02 | Lundbeck & Co As H | Metodo de elaboracion de 4,5,6,7 tetrahidroisoxazol [5,4-c] piridin-3-ol (thip) |
| EP1691811B1 (en) | 2003-12-11 | 2014-07-23 | Sunovion Pharmaceuticals Inc. | Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression |
| US20050137222A1 (en) * | 2003-12-18 | 2005-06-23 | H. Lundbeck A/S | Treatment of insomnia in human patients |
| US20050215521A1 (en) * | 2003-12-22 | 2005-09-29 | Karim Lalji | Modafinil combination therapy for improving sleep quality |
| AU2004308962A1 (en) * | 2003-12-24 | 2005-07-14 | Sepracor Inc. | Melatonin combination therapy for improving sleep quality |
| GB0402118D0 (en) * | 2004-01-30 | 2004-03-03 | Merck Sharp & Dohme | Polymorphic forms of a GABAA agonist |
| DE602005018763D1 (de) * | 2004-02-18 | 2010-02-25 | Sepracor Inc | Dopamin-agonisten-kombinationstherapie mit sedativa zur verbesserung der schlafqualität |
| GB0417558D0 (en) * | 2004-08-06 | 2004-09-08 | Merck Sharp & Dohme | Novel combination therapy |
| EP1848420A4 (en) | 2005-01-28 | 2008-01-23 | Merck & Co Inc | POLYMORPHIC FORMS OF A GABAA AGONIST |
| EP1906953A4 (en) * | 2005-04-29 | 2009-05-20 | Lundbeck & Co As H | FORMS OF ACID SALTS AND BASIC SALTS OF GABOXADOL |
| JP2009506069A (ja) | 2005-08-26 | 2009-02-12 | ブレインセルス，インコーポレイティド | ムスカリン性受容体調節による神経発生 |
| EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
| AU2006304787A1 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by PDE inhibition |
| CA2625210A1 (en) * | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US20070203216A1 (en) * | 2006-02-14 | 2007-08-30 | Bjarke Ebert | Method of treating inflammatory diseases |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| AU2007249399A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| US7678808B2 (en) | 2006-05-09 | 2010-03-16 | Braincells, Inc. | 5 HT receptor mediated neurogenesis |
| EP2068872A1 (en) | 2006-09-08 | 2009-06-17 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
| US20100193652A1 (en) * | 2009-02-02 | 2010-08-05 | William Stajos | Wall Display System And Method Of Providing The Same |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| US8784835B2 (en) * | 2012-07-02 | 2014-07-22 | Trent Austin | Method for producing muscimol and/or reducing ibotenic acid from amanita tissue |
| CN104974175A (zh) * | 2014-04-11 | 2015-10-14 | 天津药物研究院 | 一种氨甲基羟异恶唑类似物的制备方法 |
| MX2016016136A (es) | 2014-06-06 | 2017-07-05 | Ovid Therapeutics Inc | Metodos para incrementar la inhibicion tonica y para tratar insomnio secundario. |
| SI3274331T1 (sl) | 2015-03-24 | 2020-08-31 | H. Lundbeck A/S | Izdelava 4,5,6,7-tetrahidroizozaksolo (5,4-C)piridin-3-ol |
| IL305342A (en) | 2015-07-17 | 2023-10-01 | Ovid Therapeutics Inc | Methods for treating developmental disorders with gaboxadol |
| US9682069B2 (en) | 2015-07-17 | 2017-06-20 | Ovid Therapeutics Inc | Methods of treating Dravet syndrome |
| US9399034B1 (en) | 2015-08-11 | 2016-07-26 | Ovid Therapeutics Inc | Methods of sedation during critical care treatment |
| AU2017311412B2 (en) | 2016-08-11 | 2023-05-18 | Ovid Therapeutics Inc. | Methods and compositions for treatment of epileptic disorders |
| US10071083B2 (en) | 2017-02-03 | 2018-09-11 | Ovid Therapeutics Inc | Use of gaboxadol in the treatment of tinnitus |
| US20180338959A1 (en) | 2017-05-24 | 2018-11-29 | Ovid Therapeutics Inc. | Treatment of depressive disorders |
| US10813918B2 (en) | 2017-08-04 | 2020-10-27 | Ovid Therapeutics Inc. | Use of Gaboxadol in the treatment of diabetes and related conditions |
| JP2022501384A (ja) | 2018-09-20 | 2022-01-06 | オービッド・セラピューティクス・インコーポレイテッドOvid Therapeutics Inc. | トゥレット症候群、チックおよび吃音の処置のためのガボキサドールの使用 |
| WO2020106927A1 (en) | 2018-11-21 | 2020-05-28 | Certego Therapeutics | Gaboxadol for reducing risk of suicide and rapid relief of depression |
| CA3123876A1 (en) | 2018-12-17 | 2020-06-25 | Ovid Therapeutics Inc. | Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder |
| IL298334A (en) | 2020-05-20 | 2023-01-01 | Certego Therapeutics Inc | A canceled gaboxadol ring and its use for the treatment of psychiatric disorders |
| CN114292224B (zh) * | 2022-03-07 | 2022-05-20 | 中国农业科学院农产品加工研究所 | 一种大麻二酚-2-（n-乙酰基）哌啶酸酯及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2784190A (en) * | 1952-03-28 | 1957-03-05 | Upjohn Co | Alkyl piperidinepropionates |
| CA762455A (en) * | 1962-03-22 | 1967-07-04 | Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung | Pyrido-pyrimidines |
| US3381016A (en) * | 1966-03-04 | 1968-04-30 | Upjohn Co | Isoxazolo[5, 4-b]pyridine derivatives and a method for their preparation |
| DE2221770A1 (de) * | 1972-05-04 | 1973-11-15 | Bayer Ag | Verfahren zur herstellung von tetrahydropyridinen |
| DK62791A (da) * | 1991-04-09 | 1992-11-09 | Tulip Int As | Fremgangsmaade til saltning af koed samt anlaeg til brug ved udoevelse af fremgangsmaaden |
-
1978
- 1978-06-15 DK DK270278A patent/DK270278A/da unknown
- 1978-06-15 DK DK270378A patent/DK270378A/da unknown
- 1978-06-19 FI FI781954A patent/FI64376C/fi not_active IP Right Cessation
- 1978-06-19 ES ES470912A patent/ES470912A1/es not_active Expired
- 1978-06-19 FI FI781955A patent/FI781955A/fi not_active Application Discontinuation
- 1978-06-19 EP EP80106497A patent/EP0027279A1/en not_active Withdrawn
- 1978-06-19 NO NO782128A patent/NO782128L/no unknown
- 1978-06-19 NZ NZ187615A patent/NZ187615A/xx unknown
- 1978-06-19 IE IE1234/78A patent/IE47200B1/en unknown
- 1978-06-19 NO NO782127A patent/NO152049C/no unknown
- 1978-06-19 ES ES470913A patent/ES470913A1/es not_active Expired
- 1978-06-19 EP EP78100190A patent/EP0000167A1/en not_active Withdrawn
- 1978-06-19 ZA ZA00783492A patent/ZA783492B/xx unknown
- 1978-06-19 US US05/917,118 patent/US4278676A/en not_active Expired - Lifetime
- 1978-06-19 AU AU37244/78A patent/AU3724478A/en active Pending
- 1978-06-19 ZA ZA00783493A patent/ZA783493B/xx unknown
- 1978-06-19 EP EP80106498A patent/EP0028017A1/en not_active Withdrawn
- 1978-06-19 EP EP78100191A patent/EP0000338B1/en not_active Expired
- 1978-06-20 JP JP7479978A patent/JPS5436275A/ja active Pending
- 1978-06-20 IT IT7868449A patent/IT7868449A0/it unknown
- 1978-06-20 AT AT0448678A patent/AT368505B/de not_active IP Right Cessation
- 1978-06-20 CA CA305,798A patent/CA1107736A/en not_active Expired
- 1978-06-20 IT IT68450/78A patent/IT1159739B/it active
- 1978-06-20 JP JP7480078A patent/JPS5436290A/ja active Pending
- 1978-06-20 AU AU37298/78A patent/AU521040B2/en not_active Expired
-
1979
- 1979-09-03 NO NO792839A patent/NO792839L/no unknown
- 1979-12-17 US US06/104,080 patent/US4301287A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US4278676A (en) | 1981-07-14 |
| ATA448678A (de) | 1982-02-15 |
| ES470912A1 (es) | 1979-02-01 |
| ZA783492B (en) | 1979-06-27 |
| IE47200B1 (en) | 1984-01-11 |
| DK270378A (da) | 1978-12-21 |
| EP0000338A2 (en) | 1979-01-24 |
| EP0000167A1 (en) | 1979-01-10 |
| US4301287A (en) | 1981-11-17 |
| NO152049C (no) | 1985-07-24 |
| FI64376C (fi) | 1983-11-10 |
| AT368505B (de) | 1982-10-25 |
| JPS5436275A (en) | 1979-03-16 |
| NZ187615A (en) | 1981-12-15 |
| CA1107736A (en) | 1981-08-25 |
| JPS5436290A (en) | 1979-03-16 |
| NO152049B (no) | 1985-04-15 |
| FI64376B (fi) | 1983-07-29 |
| NO782127L (no) | 1978-12-21 |
| IE781234L (en) | 1978-12-20 |
| FI781955A (fi) | 1978-12-21 |
| IT7868450A0 (it) | 1978-06-20 |
| IT1159739B (it) | 1987-03-04 |
| ES470913A1 (es) | 1979-02-01 |
| EP0000338B1 (en) | 1981-11-25 |
| EP0027279A1 (en) | 1981-04-22 |
| IT7868449A0 (it) | 1978-06-20 |
| EP0028017A1 (en) | 1981-05-06 |
| DK270278A (da) | 1978-12-21 |
| EP0000338A3 (en) | 1979-06-27 |
| NO792839L (no) | 1978-12-21 |
| FI781954A (fi) | 1978-12-21 |
| AU521040B2 (en) | 1982-03-11 |
| AU3724478A (en) | 1980-01-03 |
| NO782128L (no) | 1978-12-21 |
| AU3729878A (en) | 1980-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA783493B (en) | Improvement in or relating to heterocyclic compounds | |
| ZA785989B (en) | Improvements in or relating to organic compounds | |
| ZA786081B (en) | Improvements in or relating to organic compounds | |
| ZA781443B (en) | Improvements relating to 4-acylaminophenyl-ethanolamines | |
| ZA784855B (en) | Improvements in or relating to organic compounds | |
| IL54916A0 (en) | Improvements relating to hexahydropyrimidine compounds | |
| ZA783515B (en) | Improvements in or relating to organic compounds | |
| ZA78240B (en) | Improvements in or relating to organic compounds | |
| ZA783998B (en) | Improvements in or relating to organic compounds | |
| ZA783660B (en) | Improvements in or relating to benoxaprofen | |
| HK13381A (en) | Improvements in or relating to tools | |
| ZA78521B (en) | Improvements in or relating to organic compounds | |
| ZA784435B (en) | Improvements in or relating to organic compounds | |
| ZA78430B (en) | Improvements in or relating to organic compounds | |
| ZA782963B (en) | Improvements in or relating to organic compounds | |
| ZA783708B (en) | Improvements in or relating to organic compounds | |
| ZA781714B (en) | Improvements in or relating to organic compounds | |
| ZA783516B (en) | Improvements in or relating to organic compounds | |
| ZA781085B (en) | Improvements relating to triazolothienodiazepine-1-ones | |
| DE2861017D1 (en) | Improvements in or relating to decollators | |
| ZA784273B (en) | Improvements in or relating to organic compounds | |
| ZA785061B (en) | Improvements in or relating to organic compounds | |
| PH15739A (en) | Improvements in or relating to ergoline compounds | |
| ZA786080B (en) | Improvements in or relating to organic compounds | |
| ZA781587B (en) | Improvements in or relating to organic compounds |